Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
BYDFi Lists GUNZ Token: Gunzilla Games Raises Nearly $100M, Ushering in the Next Era of AAA Web3 Gaming
-
GQG to Offer Its First Active ETF to US Investors
-
Atlantic Petroleum -Financial Calendar 2025 update – new date for Annual report and AGM
-
Atlantic Petroleum provides update on debt situation
-
Newton Golf Company to Host Fourth Quarter and Full-Year 2024 Earnings Call on March 31, 2025
-
Banijay Group: weekly share transactions
-
Constantinsborg A/S withdraws voluntary cash offer to the shareholders of FirstFarms A/S and withdraws proposal for delisting
-
Tarkett-AVAILABILITY OF THE 2024 UNIVERSAL REGISTRATION DOCUMENT
-
WEEX Drives Global Strategy with Dubai Office and TOKEN2049 Spotlight
-
NAB 2025: Vislink Set to Unveil Latest RF, 5G, Hybrid and AI Live Video Innovations
-
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
-
End of Day Message
-
Collège Boréal unveils its new five-year strategic plan: “Horizon 2030: Succeeding Together”
-
IBA – ACQUISITION OF OWN SHARES
-
BC Ferries Commissioner Approves Four New Major Vessels
-
Transfix Launches First-of-Its-Kind RFP Workflow Tool to Transform Freight Pricing with Lightning-Fast Accuracy
-
Ride the Wave: RaceTrac and Jamba Team Up for Limited-Time Swirl World Flavor
-
Alma íbúðafélag hf.: Stækkun skuldabréfaflokksins AL260128
-
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as
-
VEON Announces 2025 AGM and Board Nominees
-
Fill Her Basket with Whimsy: Arshiner Launches Easter Campaign to Bring Childhood Joy to Life
-
Suzy Appoints Brian Erickson as Chief Financial Officer
-
Vranken-Pommery Monopole - 2024 ANNUAL RESULTS - EBITDA €49,3 million
-
VEON Announces 2025 AGM and Board Nominees
-
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Onc
-
Rule 2.12 Announcement
-
Director/PDMR Shareholding
-
CORRECTION - Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2024
-
EVS Broadcast Equipment reports update of share buyback program
-
Availability of the Annual Financial Report of Societe Generale SFH for 2024
-
Whizzy Digital Named Best Marketing Agency in USA/EMEA by Stellar Business Awards
-
Transaction in Own Shares
-
Cnova N.V.: Information regarding buy-out of minority shareholders, suspension of trading and delisting
-
Net Asset Value(s)
-
Proactis SA 12 months revenue 31 January 2025
-
MacKenzie Realty Capital Announces Forbearance Agreement, Refinancing
-
McPhy Energy: 2024 Annual Results and Update on Financial Situation
-
Availability of the Annual Financial Report of Societe Generale SCF for 2024
-
Titan.ium Platform Launches Professional Services Catalog, Helps Network Operators Optimize Infrastructure
-
ASP Isotopes Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results Webinar
-
XDY Exchange Sets New Standard for Digital Asset Trading with Cutting-Edge Features
-
Yamaha Outdoor Access Initiative and Yamaha Rightwaters™ Join Forces to Expand Outdoor Recreation and Conservation Efforts
-
2024 Earnings Report
-
2024 Annual Report - ESEF Format
-
Publication of the 2024 annual report
-
Deferral of conversions between CDIs and stapled shares in respect of 2025 Unibail-Rodamco-Westfield SE Annual General Meeting
-
Michelin: TBC Corporation to divest its Midas franchise network to focus on core businesses
-
Total voting rights and Capital
-
Reporting on acquisition of treasury shares
-
Radiance Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of RB-164™, an ROR-1 Targeted ADC, for Hematologic and Solid Malignancies

